Research Report on the Biologics Market in China (Part 2)

Based on research into the Chinese biosimilar market, Frost & Sullivan has released a related industry report. The report points out that due to differences in industrial structure, the best-selling drugs in China's pharmaceutical market are very different from those in the global market. Among the top 10 most sold drugs in China in 2018, only two were biologics (insulin), while the other eight were chemical drugs. In the future, the structure of best-selling drugs in China will develop towards a global trend, with more biologics becoming blockbuster products leading in sales. This report is part two of the series; for more content, please refer to 'Research on the Chinese Biosimilar Market (Part 1)'.